Elucid
PrivateLast Round
Series D
Sep 2, 2026
Total Funding Raised
$170.75M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Elucid is a medical technology company that develops AI-powered imaging software to quantify and characterize atherosclerotic plaque for personalized cardiovascular disease treatment.
Sector
Healthcare & Life Sciences
Verticals
Medical Imaging, Medical AI, Healthcare Analytics, Medical Devices
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Elucid Comparables
Compare Elucid with similar companies based on industry and business-model similarity.
Elucid Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 2, 2026 | ||||
| Series C | Nov 9, 2023 | ||||
| Series B | Jun 22, 2022 | ||||
| Series A | May 10, 2021 | ||||
| Grant | Sep 1, 2015 |
Elucid Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bold Brain | Series B |
| IAG Capital Partners | Series B, Series A, Series D |
| MedTex Ventures | Series B, Series C, Series A |
| NIH RADx | Grant |
| Bioverge | Series B |
| Willamette Valley Capital | Series A |
| Checkmate Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 2, 2026
$55M round with IAG Capital Partners and Elevage Medical Technologies.
- Apr 15, 2026
Commercial availability of the Lesion Inspection Tool for plaque analysis.
Recent news
Latest coverage and updates
- is_developingSep 3, 2026
Elucid is developing artificial intelligence -based cardiovascular imaging platform.
- is_developingSep 2, 2026
Elucid is developing software designed to extract more detailed information from coronary CT angiography on Sep 2nd '26.
- launchesSep 2, 2026
Elucid launched BioIntegrated FFR-CT product on Sep 4th '26.
- receives_financingSep 2, 2026
Elucid received financing of $55M in Series D on Sep 2nd '26.
- attends_eventJul 6, 2026
Elucid Bioimaging Inc. attended event SCCT 2026 on Jul 9th '26.
Elucid Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Elucid's valuation, stock price, and market status.
Is Elucid a public or private company?
Elucid is a private company.
What is the current stock price of Elucid?
Elucid is a private company with no public stock price. No recent secondary market data is available.
How much is Elucid worth (valuation)?
Valuation information for Elucid is not publicly available.
Can I buy Elucid stock?
Elucid shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Elucid's last funding round?
Elucid's most recent funding round was Series C on November 9, 2023.
Who are the main investors in Elucid?
Key investors in Elucid include MedTex Ventures.
Will Elucid IPO soon?
No public IPO plans have been announced for Elucid.
How can I track Elucid secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Elucid's secondary market activity and sign up for updates.